Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Joseph McCune

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Journal of Autoimmunity|December 8, 2023
Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: The Michigan Lupus Epidemiology & Surveillance (MILES) ProgramEmily C Somers, Jaclyn M Goodrich, Lu Wang, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
The Journal of Rheumatology|March 18, 2011
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosisGunnar Tomasson, Michael Lavalley, Kahraman Tanriverdi, et al.
Frontiers in Immunology|January 2, 2025
Serum fatty acid profiles in systemic lupus erythematosus and patient reported outcomes: The Michigan Lupus Epidemiology & Surveillance (MILES) ProgramKristen N Gilley, Jenifer I Fenton, Suzanna M Zick, et al.
MMWR. Morbidity and Mortality Weekly Report|September 27, 2019
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015Emily C Somers, Jiha Lee, Afton L Hassett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Journal of Autoimmunity|October 26, 2017
CD4+CD28+KIR+CD11a<sup>hi</sup> T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patientsElizabeth Gensterblum, Paul Renauer, Patrick Coit, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Arthritis and Rheumatism|April 13, 2011
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohortFrancisco Silva, Philip Seo, Darrell R Schroeder, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Journal of Autoimmunity|December 8, 2023
Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: The Michigan Lupus Epidemiology & Surveillance (MILES) ProgramEmily C Somers, Jaclyn M Goodrich, Lu Wang, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
The Journal of Rheumatology|March 18, 2011
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosisGunnar Tomasson, Michael Lavalley, Kahraman Tanriverdi, et al.
Frontiers in Immunology|January 2, 2025
Serum fatty acid profiles in systemic lupus erythematosus and patient reported outcomes: The Michigan Lupus Epidemiology & Surveillance (MILES) ProgramKristen N Gilley, Jenifer I Fenton, Suzanna M Zick, et al.
MMWR. Morbidity and Mortality Weekly Report|September 27, 2019
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015Emily C Somers, Jiha Lee, Afton L Hassett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Journal of Autoimmunity|October 26, 2017
CD4+CD28+KIR+CD11a<sup>hi</sup> T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patientsElizabeth Gensterblum, Paul Renauer, Patrick Coit, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Arthritis and Rheumatism|April 13, 2011
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohortFrancisco Silva, Philip Seo, Darrell R Schroeder, et al.
Pageof 9